Over the past decades, bronchiectasis has been neglected, despite the global burden.1,2 To date, better diagnosis due to easy ...
Find effective medications for 'Bronchiectasis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...
The Bronchiectasis and NTM Association has accepted 27 Care Center and six Clinical Associate Center sites in 23 states and the District of Columbia into the new Bronchiectasis and NTM Care Center ...
Hosted on MSN1mon
FDA grants priority review for potential bronchiectasis treatmentBrensocatib, if approved, would be the first available treatment specifically targeting bronchiectasis, a chronic lung disease that currently has no FDA-approved therapies in the U.S. The drug is ...
The RBC analyst expects a high likelihood of approval for the bronchiectasis treatment with a favorable label, paving the way for a strong launch. Feedback from key opinion leaders (KOLs ...
This study cohort was made up of 71.3% U.K. patients with bronchiectasis. Referral to pulmonary rehabilitation was presented to 19.6% of patients. Prior to being diagnosed with bronchiectasis ...
The phase 3 trial achieved a statistically significant reduction in the frequency of exacerbations in patients with bronchiectasis, a serious, chronic lung disease with no approved treatment that ...
"Brensocatib has the potential to transform the treatment landscape for bronchiectasis and we were pleased to receive the FDA acceptance of our NDA with priority review even earlier than ...
The Bronchiectasis and NTM Association has accepted UC San Francisco (UCSF) into its Bronchiectasis and NTM Care Center Network (CCN), recognizing UCSF’s dedication to providing high-quality medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback